Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and BRAF mutations in anal carcinoma.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica - 1 Jan 2015

Serup-Hansen Eva, Linnemann Dorte, Høgdall Estrid, Geertsen Poul Flemming, Havsteen Hanne

Abstract excerpt

The EGF receptor (EGFR) is expressed in most cases of anal carcinomas. Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer and a negative correlation with Kirsten Ras (KRAS) mutation status has been proposed. The purpose of this retrospective study was to investigate the frequency and the prognostic value of KRAS and BRAF mutations in a large cohort of patients with anal cancer. One...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anus Neoplasms
Share to Carcinoma, Squamous Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histocytochemistry

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 25244542
DOI: 10.1111/apm.12306

Genes

KRAS
BRAF
EGFR
EGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and BRAF mutations in anal carcinoma.PMID 25244542Read ↗

Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.Semantic proximity Read ↗

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Semantic proximity Read ↗

Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.Semantic proximity Read ↗

KRAS and BRAF mutations in Nigerian colorectal cancers.Semantic proximity Read ↗

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Semantic proximity Read ↗

Concomitant Non-V600E BRAF and KRAS Mutations in Colorectal Carcinoma by Next-Generation Sequencing: A Distinct Subtype.Semantic proximity Read ↗

Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.Semantic proximity Read ↗

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.Semantic proximity Read ↗

Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.Semantic proximity Read ↗

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.Semantic proximity Read ↗

Molecular biology of anal squamous cell carcinoma: implications for future research and clinical intervention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.